Combination of copper-chelating agent, trientine, and methotrexate attenuates colorectal carcinoma development and angiogenesis in mice.

@article{Yoshiji2005CombinationOC,
  title={Combination of copper-chelating agent, trientine, and methotrexate attenuates colorectal carcinoma development and angiogenesis in mice.},
  author={Hitoshi Yoshiji and Junichi Yoshii and Shigeki Kuriyama and Yasuhide Ikenaka and Ryuichi Noguchi and Koji Yanase and Tadashi Namisaki and Mitsuteru Kitade and Masaharu Yamazaki and Hiroshi Fukui},
  journal={Oncology reports},
  year={2005},
  volume={14 1},
  pages={
          213-8
        }
}
Recent studies have suggested that an anti-angiogenic agent could improve the inhibitory effects of standard chemotherapeutic drugs against tumor development. We previously reported that the clinically used copper-chelating agent, trientine dihydrochloride (trientine), exerted strong anti-angiogenic activity and inhibited tumor growth. The aim of the current study was to examine the combined effect of trientine and methotrexate on the development and angiogenesis of xenograft human colorectal… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-5 of 5 citations